Anna Bruckner
Concepts (473)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epidermolysis Bullosa | 33 | 2026 | 69 | 8.170 |
Why?
| | Epidermolysis Bullosa Dystrophica | 15 | 2025 | 41 | 2.970 |
Why?
| | Hemangioma | 9 | 2016 | 46 | 2.470 |
Why?
| | Dermatology | 8 | 2025 | 130 | 2.400 |
Why?
| | Skin Neoplasms | 12 | 2024 | 849 | 1.670 |
Why?
| | Collagen Type VII | 5 | 2025 | 27 | 1.500 |
Why?
| | Epidermolysis Bullosa Simplex | 4 | 2026 | 14 | 1.340 |
Why?
| | Organic Chemicals | 4 | 2026 | 112 | 1.300 |
Why?
| | Skin | 11 | 2026 | 753 | 1.180 |
Why?
| | Acne Vulgaris | 2 | 2022 | 25 | 1.100 |
Why?
| | Bandages | 1 | 2025 | 41 | 0.890 |
Why?
| | Dermatologic Agents | 3 | 2025 | 68 | 0.810 |
Why?
| | Lymphatic Abnormalities | 2 | 2014 | 20 | 0.760 |
Why?
| | Severity of Illness Index | 9 | 2025 | 2930 | 0.740 |
Why?
| | Ichthyosis, Lamellar | 3 | 2022 | 9 | 0.720 |
Why?
| | Humans | 109 | 2026 | 145474 | 0.710 |
Why?
| | Child | 47 | 2026 | 22707 | 0.710 |
Why?
| | Gentamicins | 1 | 2022 | 50 | 0.700 |
Why?
| | Epidermolysis Bullosa, Junctional | 4 | 2026 | 9 | 0.700 |
Why?
| | Infant | 27 | 2025 | 10077 | 0.650 |
Why?
| | Chilblains | 1 | 2020 | 3 | 0.650 |
Why?
| | Betacoronavirus | 2 | 2020 | 288 | 0.640 |
Why?
| | Alopecia | 2 | 2012 | 37 | 0.640 |
Why?
| | Wound Healing | 5 | 2026 | 355 | 0.620 |
Why?
| | Dermatitis, Allergic Contact | 4 | 2002 | 73 | 0.620 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2020 | 37 | 0.600 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2020 | 55 | 0.590 |
Why?
| | Exanthema | 1 | 2020 | 86 | 0.590 |
Why?
| | Isotretinoin | 2 | 2022 | 26 | 0.580 |
Why?
| | Diagnosis, Differential | 13 | 2015 | 1508 | 0.570 |
Why?
| | Ichthyosis | 3 | 2025 | 15 | 0.570 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 389 | 0.550 |
Why?
| | Coronavirus Infections | 2 | 2020 | 383 | 0.550 |
Why?
| | Skin Diseases | 3 | 2011 | 152 | 0.550 |
Why?
| | Pandemics | 4 | 2023 | 1707 | 0.550 |
Why?
| | Mandelic Acids | 1 | 2018 | 2 | 0.540 |
Why?
| | Parasympatholytics | 1 | 2018 | 11 | 0.540 |
Why?
| | Adolescent | 28 | 2026 | 22529 | 0.540 |
Why?
| | Hyperhidrosis | 1 | 2018 | 6 | 0.540 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 177 | 0.530 |
Why?
| | GTP-Binding Protein alpha Subunits | 2 | 2016 | 15 | 0.520 |
Why?
| | Infant, Newborn | 16 | 2026 | 6447 | 0.500 |
Why?
| | Child, Preschool | 22 | 2026 | 11853 | 0.500 |
Why?
| | Dermatitis, Atopic | 2 | 2017 | 322 | 0.500 |
Why?
| | Education, Distance | 1 | 2017 | 59 | 0.500 |
Why?
| | Vascular Neoplasms | 2 | 2016 | 18 | 0.490 |
Why?
| | Male | 51 | 2026 | 72842 | 0.480 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2016 | 58 | 0.470 |
Why?
| | Female | 49 | 2026 | 78844 | 0.470 |
Why?
| | Telemedicine | 2 | 2023 | 961 | 0.460 |
Why?
| | Histiocytosis | 1 | 2015 | 9 | 0.460 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 27 | 0.460 |
Why?
| | Mutation | 8 | 2026 | 4075 | 0.450 |
Why?
| | Alopecia Areata | 2 | 2022 | 13 | 0.430 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2015 | 36 | 0.430 |
Why?
| | Nevus, Pigmented | 1 | 2015 | 35 | 0.430 |
Why?
| | Rare Diseases | 1 | 2015 | 116 | 0.430 |
Why?
| | Thrombocytopenia | 2 | 2016 | 204 | 0.430 |
Why?
| | Triterpenes | 2 | 2026 | 27 | 0.420 |
Why?
| | Anemia | 5 | 2023 | 191 | 0.420 |
Why?
| | Endothelium, Lymphatic | 1 | 2014 | 11 | 0.410 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2014 | 23 | 0.410 |
Why?
| | Sweat Gland Neoplasms | 2 | 2011 | 8 | 0.410 |
Why?
| | Hydrops Fetalis | 1 | 2014 | 13 | 0.410 |
Why?
| | Drug Eruptions | 1 | 2013 | 28 | 0.400 |
Why?
| | Propranolol | 2 | 2011 | 44 | 0.390 |
Why?
| | Young Adult | 16 | 2025 | 14218 | 0.390 |
Why?
| | Hemangioendothelioma | 1 | 2012 | 13 | 0.370 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2012 | 8 | 0.370 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2013 | 156 | 0.370 |
Why?
| | Langer-Giedion Syndrome | 1 | 2012 | 2 | 0.360 |
Why?
| | Hair Diseases | 1 | 2012 | 10 | 0.360 |
Why?
| | Clinical Competence | 3 | 2025 | 1243 | 0.350 |
Why?
| | Bone Demineralization, Pathologic | 1 | 2011 | 2 | 0.350 |
Why?
| | Sarcoma, Kaposi | 1 | 2012 | 83 | 0.350 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2012 | 40 | 0.350 |
Why?
| | Calcification, Physiologic | 1 | 2011 | 29 | 0.350 |
Why?
| | Microscopy, Fluorescence | 1 | 2013 | 408 | 0.340 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2014 | 449 | 0.340 |
Why?
| | Bone Diseases, Metabolic | 2 | 2011 | 58 | 0.340 |
Why?
| | Sulfones | 1 | 2012 | 127 | 0.340 |
Why?
| | Internship and Residency | 2 | 2022 | 1267 | 0.330 |
Why?
| | 2-Propanol | 1 | 2011 | 20 | 0.330 |
Why?
| | Facial Neoplasms | 1 | 2011 | 19 | 0.330 |
Why?
| | Facial Dermatoses | 2 | 2010 | 17 | 0.330 |
Why?
| | Dermis | 2 | 2011 | 31 | 0.330 |
Why?
| | Gene Deletion | 1 | 2012 | 391 | 0.320 |
Why?
| | Pediatrics | 2 | 2025 | 1121 | 0.320 |
Why?
| | Bone Density | 2 | 2011 | 487 | 0.320 |
Why?
| | Hyperpigmentation | 1 | 2011 | 27 | 0.320 |
Why?
| | Genes, Recessive | 3 | 2025 | 78 | 0.320 |
Why?
| | Solvents | 1 | 2011 | 112 | 0.320 |
Why?
| | Ferrochelatase | 1 | 2010 | 1 | 0.320 |
Why?
| | Porphyria, Erythropoietic | 1 | 2010 | 2 | 0.320 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2010 | 15 | 0.310 |
Why?
| | Desmoplakins | 1 | 2010 | 24 | 0.310 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2378 | 0.310 |
Why?
| | Tumor Burden | 1 | 2011 | 325 | 0.310 |
Why?
| | Xanthomatosis | 1 | 2009 | 8 | 0.310 |
Why?
| | Laryngeal Neoplasms | 1 | 2010 | 36 | 0.300 |
Why?
| | Immunohistochemistry | 5 | 2019 | 1716 | 0.300 |
Why?
| | Mediastinal Neoplasms | 1 | 2010 | 53 | 0.300 |
Why?
| | Granuloma | 1 | 2010 | 97 | 0.300 |
Why?
| | Carcinoma | 2 | 2011 | 225 | 0.290 |
Why?
| | Piperazines | 1 | 2012 | 375 | 0.290 |
Why?
| | Treatment Outcome | 11 | 2026 | 11772 | 0.280 |
Why?
| | Parakeratosis | 1 | 2008 | 1 | 0.280 |
Why?
| | Pruritus | 3 | 2014 | 59 | 0.280 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2010 | 252 | 0.280 |
Why?
| | Palliative Care | 2 | 2026 | 1020 | 0.270 |
Why?
| | Canada | 3 | 2020 | 431 | 0.260 |
Why?
| | Self-Help Groups | 1 | 2007 | 36 | 0.260 |
Why?
| | Dermatitis, Exfoliative | 1 | 2006 | 3 | 0.250 |
Why?
| | Hand Dermatoses | 1 | 2006 | 7 | 0.250 |
Why?
| | Immunoglobulin A | 3 | 2018 | 214 | 0.240 |
Why?
| | Ethics, Medical | 1 | 2007 | 90 | 0.240 |
Why?
| | Pemphigus | 1 | 2005 | 8 | 0.230 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2022 | 641 | 0.230 |
Why?
| | Specialty Boards | 1 | 2025 | 42 | 0.220 |
Why?
| | Netherton Syndrome | 1 | 2025 | 3 | 0.220 |
Why?
| | Hamartoma | 1 | 2005 | 29 | 0.220 |
Why?
| | Ichthyosiform Erythroderma, Congenital | 1 | 2025 | 6 | 0.220 |
Why?
| | Skin Pigmentation | 1 | 2025 | 48 | 0.220 |
Why?
| | Prospective Studies | 4 | 2022 | 8057 | 0.220 |
Why?
| | Cost Savings | 1 | 2025 | 86 | 0.220 |
Why?
| | Phytotherapy | 1 | 2025 | 74 | 0.220 |
Why?
| | Biopsy, Needle | 3 | 2019 | 185 | 0.220 |
Why?
| | Incontinentia Pigmenti | 1 | 2004 | 3 | 0.210 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1371 | 0.210 |
Why?
| | Homozygote | 1 | 2025 | 199 | 0.210 |
Why?
| | Observer Variation | 4 | 2022 | 357 | 0.210 |
Why?
| | Education, Medical, Continuing | 1 | 2025 | 133 | 0.210 |
Why?
| | Certification | 1 | 2025 | 119 | 0.210 |
Why?
| | Adult | 18 | 2025 | 40777 | 0.210 |
Why?
| | Biopsy | 3 | 2015 | 1082 | 0.200 |
Why?
| | Sarcoma, Clear Cell | 1 | 2024 | 10 | 0.200 |
Why?
| | Transcription Factors | 1 | 2012 | 1734 | 0.200 |
Why?
| | Introns | 1 | 2025 | 255 | 0.200 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2024 | 78 | 0.200 |
Why?
| | North America | 3 | 2021 | 302 | 0.200 |
Why?
| | Scalp | 1 | 2024 | 38 | 0.200 |
Why?
| | Immunoglobulin G | 3 | 2018 | 892 | 0.200 |
Why?
| | Water | 1 | 2006 | 445 | 0.200 |
Why?
| | Plant Extracts | 1 | 2025 | 188 | 0.190 |
Why?
| | Administration, Topical | 3 | 2020 | 153 | 0.190 |
Why?
| | Aspirin | 1 | 2006 | 406 | 0.190 |
Why?
| | Genetic Association Studies | 1 | 2025 | 369 | 0.190 |
Why?
| | Privacy | 1 | 2023 | 41 | 0.190 |
Why?
| | Phenotype | 3 | 2025 | 3155 | 0.190 |
Why?
| | Confidentiality | 1 | 2023 | 80 | 0.190 |
Why?
| | Transition to Adult Care | 1 | 2024 | 103 | 0.190 |
Why?
| | Retrospective Studies | 13 | 2025 | 17291 | 0.180 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2006 | 499 | 0.180 |
Why?
| | Skin Care | 2 | 2020 | 22 | 0.180 |
Why?
| | Decision Support Techniques | 1 | 2007 | 477 | 0.180 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2022 | 16 | 0.180 |
Why?
| | Middle Aged | 11 | 2025 | 36215 | 0.170 |
Why?
| | Competency-Based Education | 1 | 2022 | 81 | 0.170 |
Why?
| | Consensus | 3 | 2024 | 477 | 0.170 |
Why?
| | Jews | 1 | 2021 | 20 | 0.170 |
Why?
| | Cohort Studies | 4 | 2022 | 6013 | 0.170 |
Why?
| | Administration, Intravenous | 1 | 2022 | 172 | 0.170 |
Why?
| | Rhabdomyosarcoma | 1 | 2022 | 65 | 0.170 |
Why?
| | Fatal Outcome | 2 | 2014 | 305 | 0.170 |
Why?
| | Biological Products | 1 | 2025 | 257 | 0.170 |
Why?
| | Parents | 3 | 2026 | 1403 | 0.170 |
Why?
| | Adrenal Cortex Hormones | 2 | 2014 | 484 | 0.170 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2024 | 273 | 0.170 |
Why?
| | Quality of Life | 4 | 2025 | 3204 | 0.160 |
Why?
| | Anesthetics | 1 | 2022 | 99 | 0.160 |
Why?
| | Toes | 1 | 2020 | 16 | 0.160 |
Why?
| | NF-kappa B | 1 | 2004 | 666 | 0.160 |
Why?
| | Absorptiometry, Photon | 2 | 2011 | 277 | 0.160 |
Why?
| | Pseudomonas aeruginosa | 1 | 2023 | 395 | 0.160 |
Why?
| | Follow-Up Studies | 4 | 2019 | 5423 | 0.160 |
Why?
| | Detergents | 1 | 2020 | 43 | 0.150 |
Why?
| | Mycoplasma pneumoniae | 1 | 2020 | 53 | 0.150 |
Why?
| | Mouth Diseases | 2 | 2013 | 47 | 0.150 |
Why?
| | Mouth Mucosa | 2 | 2013 | 85 | 0.150 |
Why?
| | Double-Blind Method | 4 | 2026 | 2062 | 0.150 |
Why?
| | Kidney Neoplasms | 1 | 2024 | 413 | 0.150 |
Why?
| | Iron | 3 | 2023 | 357 | 0.150 |
Why?
| | Prenatal Diagnosis | 2 | 2014 | 196 | 0.150 |
Why?
| | APOBEC Deaminases | 1 | 2018 | 6 | 0.140 |
Why?
| | Decision Making | 1 | 2026 | 977 | 0.140 |
Why?
| | Cytosine Deaminase | 1 | 2018 | 15 | 0.140 |
Why?
| | Linear IgA Bullous Dermatosis | 1 | 2018 | 1 | 0.140 |
Why?
| | Dilatation | 1 | 2018 | 71 | 0.140 |
Why?
| | Administration, Oral | 2 | 2012 | 866 | 0.140 |
Why?
| | Esophageal Stenosis | 1 | 2018 | 60 | 0.140 |
Why?
| | Fluoroscopy | 1 | 2018 | 180 | 0.130 |
Why?
| | Chronic Pain | 1 | 2022 | 291 | 0.130 |
Why?
| | Age Distribution | 1 | 2019 | 403 | 0.130 |
Why?
| | Sex Distribution | 1 | 2019 | 387 | 0.130 |
Why?
| | Patient Satisfaction | 1 | 2022 | 709 | 0.130 |
Why?
| | Cost of Illness | 1 | 2020 | 324 | 0.130 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 562 | 0.130 |
Why?
| | Esophagoscopy | 1 | 2018 | 223 | 0.120 |
Why?
| | Surveys and Questionnaires | 5 | 2024 | 6066 | 0.120 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2016 | 34 | 0.120 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2016 | 19 | 0.120 |
Why?
| | Databases, Factual | 2 | 2020 | 1490 | 0.120 |
Why?
| | Staphylococcal Infections | 1 | 2020 | 391 | 0.120 |
Why?
| | Incidence | 2 | 2022 | 2923 | 0.110 |
Why?
| | United States | 5 | 2025 | 16098 | 0.110 |
Why?
| | Survival Analysis | 1 | 2019 | 1374 | 0.110 |
Why?
| | Risk Assessment | 3 | 2019 | 3747 | 0.110 |
Why?
| | Clobetasol | 1 | 2015 | 7 | 0.110 |
Why?
| | Pachyonychia Congenita | 1 | 2015 | 4 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2016 | 288 | 0.110 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2022 | 686 | 0.110 |
Why?
| | Patient Care Team | 1 | 2020 | 696 | 0.100 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 307 | 0.100 |
Why?
| | Keratins | 1 | 2015 | 171 | 0.100 |
Why?
| | Antigens, CD34 | 1 | 2014 | 89 | 0.100 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 191 | 0.100 |
Why?
| | Prednisolone | 2 | 2013 | 67 | 0.100 |
Why?
| | Photography | 2 | 2025 | 119 | 0.100 |
Why?
| | Disease Progression | 2 | 2019 | 2864 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 3 | 2014 | 477 | 0.100 |
Why?
| | Pemphigoid, Bullous | 1 | 2013 | 7 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1997 | 0.100 |
Why?
| | Fluorescent Antibody Technique | 2 | 2021 | 365 | 0.090 |
Why?
| | Remission, Spontaneous | 1 | 2012 | 39 | 0.090 |
Why?
| | Skin Diseases, Papulosquamous | 1 | 2012 | 2 | 0.090 |
Why?
| | Erythema | 3 | 2022 | 28 | 0.090 |
Why?
| | Prednisone | 2 | 2005 | 224 | 0.090 |
Why?
| | Transcriptome | 2 | 2018 | 1038 | 0.090 |
Why?
| | Oropharynx | 1 | 2012 | 46 | 0.090 |
Why?
| | Pilot Projects | 1 | 2018 | 1891 | 0.090 |
Why?
| | Sildenafil Citrate | 1 | 2012 | 60 | 0.090 |
Why?
| | Panniculitis | 1 | 2011 | 3 | 0.090 |
Why?
| | Actins | 1 | 2014 | 425 | 0.090 |
Why?
| | Carcinoma, Verrucous | 1 | 2011 | 3 | 0.090 |
Why?
| | Fractures, Compression | 1 | 2011 | 16 | 0.090 |
Why?
| | Nose | 1 | 2012 | 67 | 0.090 |
Why?
| | Age Determination by Skeleton | 1 | 2011 | 16 | 0.090 |
Why?
| | Blood Sedimentation | 1 | 2011 | 37 | 0.090 |
Why?
| | Dwarfism | 1 | 2011 | 14 | 0.080 |
Why?
| | Calcifediol | 1 | 2011 | 31 | 0.080 |
Why?
| | Fingers | 1 | 2012 | 107 | 0.080 |
Why?
| | Reproducibility of Results | 4 | 2025 | 3413 | 0.080 |
Why?
| | Subcutaneous Fat | 1 | 2011 | 79 | 0.080 |
Why?
| | Spinal Fractures | 1 | 2011 | 76 | 0.080 |
Why?
| | Mobility Limitation | 1 | 2011 | 67 | 0.080 |
Why?
| | Purines | 1 | 2012 | 187 | 0.080 |
Why?
| | Body Size | 1 | 2011 | 88 | 0.080 |
Why?
| | Caregivers | 1 | 2020 | 1073 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2015 | 531 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2015 | 2803 | 0.080 |
Why?
| | Darier Disease | 1 | 2010 | 2 | 0.080 |
Why?
| | Vincristine | 1 | 2011 | 142 | 0.080 |
Why?
| | Serum Albumin | 1 | 2011 | 147 | 0.080 |
Why?
| | Autoantibodies | 1 | 2018 | 1509 | 0.080 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2010 | 32 | 0.080 |
Why?
| | Body Height | 1 | 2011 | 202 | 0.080 |
Why?
| | Drug Therapy, Combination | 2 | 2011 | 1044 | 0.080 |
Why?
| | Steroids | 1 | 2011 | 160 | 0.080 |
Why?
| | Sequence Analysis, DNA | 2 | 2010 | 777 | 0.080 |
Why?
| | Porphyrins | 1 | 2010 | 16 | 0.080 |
Why?
| | Hypothermia, Induced | 1 | 2011 | 95 | 0.080 |
Why?
| | Patch Tests | 2 | 2001 | 60 | 0.080 |
Why?
| | Keratinocytes | 2 | 2024 | 249 | 0.080 |
Why?
| | Clarithromycin | 1 | 2010 | 24 | 0.080 |
Why?
| | Consanguinity | 1 | 2010 | 49 | 0.080 |
Why?
| | Erythromycin | 1 | 2010 | 19 | 0.080 |
Why?
| | Infant, Newborn, Diseases | 1 | 2011 | 115 | 0.080 |
Why?
| | Foam Cells | 1 | 2009 | 17 | 0.080 |
Why?
| | Ointments | 2 | 2023 | 25 | 0.080 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1923 | 0.080 |
Why?
| | Porokeratosis | 1 | 2009 | 1 | 0.080 |
Why?
| | Nevus, Intradermal | 1 | 2009 | 3 | 0.080 |
Why?
| | Keratosis | 1 | 2009 | 16 | 0.080 |
Why?
| | Sequence Deletion | 1 | 2010 | 190 | 0.070 |
Why?
| | Staining and Labeling | 1 | 2010 | 153 | 0.070 |
Why?
| | Respiratory Sounds | 1 | 2010 | 103 | 0.070 |
Why?
| | Radiography | 1 | 2012 | 852 | 0.070 |
Why?
| | Epidermodysplasia Verruciformis | 1 | 2009 | 1 | 0.070 |
Why?
| | Basement Membrane | 2 | 2007 | 32 | 0.070 |
Why?
| | Lumbar Vertebrae | 1 | 2011 | 252 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2015 | 699 | 0.070 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2011 | 317 | 0.070 |
Why?
| | C-Reactive Protein | 1 | 2011 | 422 | 0.070 |
Why?
| | Dapsone | 2 | 2005 | 8 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1419 | 0.070 |
Why?
| | Diaper Rash | 1 | 2008 | 5 | 0.070 |
Why?
| | Hemoglobins | 1 | 2011 | 386 | 0.070 |
Why?
| | Blister | 3 | 2013 | 39 | 0.070 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2010 | 193 | 0.070 |
Why?
| | Immune System Diseases | 1 | 2008 | 37 | 0.070 |
Why?
| | Airway Obstruction | 1 | 2010 | 153 | 0.070 |
Why?
| | Hair | 1 | 2008 | 84 | 0.070 |
Why?
| | Psychophysiologic Disorders | 1 | 2007 | 10 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2011 | 558 | 0.070 |
Why?
| | Aged | 4 | 2025 | 26153 | 0.070 |
Why?
| | Weight Gain | 1 | 2011 | 561 | 0.070 |
Why?
| | Anti-Anxiety Agents | 1 | 2007 | 48 | 0.060 |
Why?
| | Euthanasia, Passive | 1 | 2007 | 2 | 0.060 |
Why?
| | Ethics Committees | 1 | 2007 | 4 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 956 | 0.060 |
Why?
| | Biomedical Research | 1 | 2014 | 717 | 0.060 |
Why?
| | Androgens | 1 | 2008 | 181 | 0.060 |
Why?
| | Hematinics | 1 | 2006 | 22 | 0.060 |
Why?
| | Patient Advocacy | 1 | 2007 | 73 | 0.060 |
Why?
| | Interdisciplinary Communication | 2 | 2020 | 200 | 0.060 |
Why?
| | Ferric Compounds | 1 | 2006 | 54 | 0.060 |
Why?
| | Erythropoietin | 1 | 2006 | 100 | 0.060 |
Why?
| | Professional-Family Relations | 1 | 2007 | 153 | 0.060 |
Why?
| | Desmoglein 3 | 1 | 2005 | 14 | 0.060 |
Why?
| | Dermatologists | 1 | 2025 | 7 | 0.060 |
Why?
| | Antidepressive Agents | 1 | 2007 | 242 | 0.060 |
Why?
| | Plant Bark | 1 | 2025 | 11 | 0.060 |
Why?
| | Antipsychotic Agents | 1 | 2007 | 211 | 0.060 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2005 | 17 | 0.060 |
Why?
| | California | 1 | 2007 | 471 | 0.060 |
Why?
| | Social Environment | 1 | 2007 | 252 | 0.060 |
Why?
| | Colonic Diseases | 1 | 2005 | 37 | 0.060 |
Why?
| | Cellulitis | 1 | 2005 | 54 | 0.060 |
Why?
| | Genetic Therapy | 1 | 2007 | 316 | 0.060 |
Why?
| | Physicians | 1 | 2014 | 955 | 0.050 |
Why?
| | Calcium | 1 | 2011 | 1190 | 0.050 |
Why?
| | Fibroblasts | 2 | 2024 | 1025 | 0.050 |
Why?
| | Dermatitis Herpetiformis | 1 | 2004 | 2 | 0.050 |
Why?
| | Epidermis | 1 | 2005 | 156 | 0.050 |
Why?
| | Immunosuppressive Agents | 2 | 2015 | 838 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2011 | 776 | 0.050 |
Why?
| | Urticaria | 1 | 2004 | 38 | 0.050 |
Why?
| | Skin Transplantation | 1 | 2024 | 85 | 0.050 |
Why?
| | Neutrophils | 1 | 2009 | 1124 | 0.050 |
Why?
| | Anthraquinones | 1 | 2023 | 10 | 0.050 |
Why?
| | Gene Editing | 1 | 2024 | 89 | 0.050 |
Why?
| | Excipients | 1 | 2023 | 55 | 0.050 |
Why?
| | Betula | 1 | 2023 | 3 | 0.050 |
Why?
| | Transplantation, Autologous | 1 | 2024 | 300 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 848 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 397 | 0.050 |
Why?
| | Catastrophization | 1 | 2022 | 16 | 0.050 |
Why?
| | Eosinophilia | 1 | 2005 | 223 | 0.050 |
Why?
| | Pregnancy | 2 | 2014 | 7202 | 0.050 |
Why?
| | Histamine H1 Antagonists | 1 | 2002 | 24 | 0.050 |
Why?
| | Needs Assessment | 1 | 2025 | 402 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2024 | 166 | 0.050 |
Why?
| | Communicable Disease Control | 1 | 2023 | 85 | 0.050 |
Why?
| | Social Support | 1 | 2007 | 646 | 0.050 |
Why?
| | Autoantigens | 1 | 2005 | 427 | 0.050 |
Why?
| | Mucous Membrane | 2 | 2014 | 128 | 0.050 |
Why?
| | Professionalism | 1 | 2022 | 26 | 0.050 |
Why?
| | Algorithms | 2 | 2007 | 1845 | 0.050 |
Why?
| | Family | 1 | 2007 | 682 | 0.050 |
Why?
| | Delphi Technique | 1 | 2024 | 332 | 0.050 |
Why?
| | Atrophy | 2 | 2013 | 199 | 0.040 |
Why?
| | Accreditation | 1 | 2022 | 101 | 0.040 |
Why?
| | Germ Cells | 1 | 2022 | 65 | 0.040 |
Why?
| | Chile | 1 | 2021 | 27 | 0.040 |
Why?
| | Colombia | 1 | 2021 | 42 | 0.040 |
Why?
| | Prevalence | 2 | 2022 | 2865 | 0.040 |
Why?
| | Social Class | 1 | 2023 | 264 | 0.040 |
Why?
| | Blood Protein Electrophoresis | 1 | 1981 | 6 | 0.040 |
Why?
| | Nephelometry and Turbidimetry | 1 | 1981 | 15 | 0.040 |
Why?
| | Mupirocin | 1 | 2020 | 7 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5904 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 466 | 0.040 |
Why?
| | Information Dissemination | 1 | 2023 | 224 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2022 | 195 | 0.040 |
Why?
| | Mexico | 1 | 2021 | 233 | 0.040 |
Why?
| | Retinoids | 1 | 2020 | 33 | 0.040 |
Why?
| | Immunoglobulins | 1 | 1981 | 162 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1852 | 0.040 |
Why?
| | Language | 1 | 2023 | 323 | 0.040 |
Why?
| | Minority Groups | 1 | 2022 | 284 | 0.040 |
Why?
| | Inflammation | 1 | 2011 | 2878 | 0.040 |
Why?
| | Desmocollins | 1 | 2018 | 2 | 0.030 |
Why?
| | Mutation Rate | 1 | 2018 | 33 | 0.030 |
Why?
| | Desmogleins | 1 | 2018 | 3 | 0.030 |
Why?
| | Age of Onset | 1 | 2000 | 555 | 0.030 |
Why?
| | Cosmetics | 1 | 2020 | 76 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 184 | 0.030 |
Why?
| | Mutagenesis | 1 | 2018 | 194 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3904 | 0.030 |
Why?
| | Self Care | 1 | 2020 | 390 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2020 | 451 | 0.030 |
Why?
| | Esophagus | 1 | 2018 | 262 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2024 | 2046 | 0.030 |
Why?
| | Health Personnel | 1 | 2023 | 754 | 0.030 |
Why?
| | Melanocytes | 1 | 2016 | 65 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2024 | 1193 | 0.030 |
Why?
| | DNA Repair | 1 | 2018 | 254 | 0.030 |
Why?
| | Pain | 2 | 2015 | 789 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2016 | 104 | 0.030 |
Why?
| | Age Factors | 2 | 2014 | 3342 | 0.030 |
Why?
| | Alemtuzumab | 1 | 2015 | 15 | 0.030 |
Why?
| | Myeloablative Agonists | 1 | 2015 | 23 | 0.030 |
Why?
| | Busulfan | 1 | 2015 | 15 | 0.030 |
Why?
| | Vidarabine | 1 | 2015 | 32 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 946 | 0.030 |
Why?
| | Keratin-16 | 1 | 2015 | 1 | 0.030 |
Why?
| | Keratin-6 | 1 | 2015 | 6 | 0.030 |
Why?
| | Keratin-17 | 1 | 2015 | 4 | 0.030 |
Why?
| | Skin Cream | 1 | 2014 | 11 | 0.030 |
Why?
| | Oils | 1 | 2014 | 22 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2016 | 762 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2016 | 376 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 69 | 0.030 |
Why?
| | Enzymes | 1 | 2015 | 60 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 440 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2015 | 418 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2022 | 1196 | 0.030 |
Why?
| | Oral Medicine | 1 | 2013 | 1 | 0.020 |
Why?
| | Lip Diseases | 1 | 2013 | 7 | 0.020 |
Why?
| | Tongue Diseases | 1 | 2013 | 9 | 0.020 |
Why?
| | Hospitalization | 1 | 2024 | 2460 | 0.020 |
Why?
| | HIV Infections | 1 | 2009 | 3193 | 0.020 |
Why?
| | Palate | 1 | 2013 | 40 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 749 | 0.020 |
Why?
| | Receptor, Macrophage Colony-Stimulating Factor | 1 | 1992 | 12 | 0.020 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 1992 | 20 | 0.020 |
Why?
| | Microstomia | 1 | 2012 | 1 | 0.020 |
Why?
| | Ankyloglossia | 1 | 2012 | 2 | 0.020 |
Why?
| | Mouth Abnormalities | 1 | 2012 | 3 | 0.020 |
Why?
| | Down-Regulation | 1 | 2015 | 618 | 0.020 |
Why?
| | Dental Enamel Hypoplasia | 1 | 2012 | 8 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1443 | 0.020 |
Why?
| | Ulcer | 1 | 2012 | 37 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1581 | 0.020 |
Why?
| | Risk Factors | 1 | 2006 | 10885 | 0.020 |
Why?
| | Back | 1 | 2011 | 12 | 0.020 |
Why?
| | Up-Regulation | 1 | 2015 | 847 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 462 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1266 | 0.020 |
Why?
| | Cicatrix | 1 | 2012 | 69 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 330 | 0.020 |
Why?
| | Therapeutics | 1 | 2011 | 14 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 428 | 0.020 |
Why?
| | Animals | 2 | 2024 | 38030 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 1992 | 506 | 0.020 |
Why?
| | Necrosis | 1 | 2011 | 244 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2014 | 586 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2011 | 178 | 0.020 |
Why?
| | Elastic Tissue | 1 | 2009 | 10 | 0.020 |
Why?
| | Hair Follicle | 1 | 2009 | 49 | 0.020 |
Why?
| | Vasodilator Agents | 1 | 2011 | 330 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 407 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2015 | 992 | 0.020 |
Why?
| | Neck | 1 | 2009 | 108 | 0.020 |
Why?
| | Exons | 1 | 2010 | 363 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2015 | 1131 | 0.020 |
Why?
| | Arm | 1 | 2009 | 110 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2016 | 4148 | 0.020 |
Why?
| | Resuscitation | 1 | 2011 | 310 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2014 | 867 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 1767 | 0.020 |
Why?
| | Skin Diseases, Genetic | 1 | 2007 | 13 | 0.020 |
Why?
| | Preimplantation Diagnosis | 1 | 2007 | 7 | 0.020 |
Why?
| | Heart Arrest | 1 | 2011 | 410 | 0.020 |
Why?
| | Darbepoetin alfa | 1 | 2006 | 3 | 0.020 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2007 | 59 | 0.020 |
Why?
| | Mice | 1 | 2024 | 18329 | 0.020 |
Why?
| | Wound Infection | 1 | 2007 | 60 | 0.020 |
Why?
| | Malnutrition | 1 | 2007 | 86 | 0.010 |
Why?
| | Prognosis | 1 | 2014 | 4316 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2018 | 8333 | 0.010 |
Why?
| | Fetal Diseases | 1 | 2007 | 194 | 0.010 |
Why?
| | Syndrome | 1 | 2005 | 381 | 0.010 |
Why?
| | Primary Health Care | 1 | 2014 | 1735 | 0.010 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 345 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2013 | 2381 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 1981 | 265 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1808 | 0.010 |
Why?
| | Proto-Oncogenes | 1 | 1992 | 28 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1992 | 2028 | 0.000 |
Why?
| | Cell Line | 1 | 1992 | 2823 | 0.000 |
Why?
| | Adenocarcinoma | 1 | 1992 | 925 | 0.000 |
Why?
| | Cytokines | 1 | 1992 | 2067 | 0.000 |
Why?
|
|
Bruckner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|